Applications

MNP nanotechnology is broad based and amenable to formulating more than 60% of currently approved APIs.

We have achieved therapeutic blood levels with over 20 molecules from multiple therapeutic categories.

Key salient features of the MNP Nanoformulations:

• Rapid uptake; quick penetration
• Sustained release; depot effect
  • Once a day application feasible for most drugs
• Flexibility in altering characteristics of formulation
• High drug loading capability (up to 20% w/w achieved so far)
• Unlimited skin surface area (unlike patches)
• Same formulation can be used to deliver different amounts of drug – by varying application volumes

SGN Nanopharma offers a much broader physicochemical property range of APIs that can be delivered via MNP as compared to other technologies.

• First to deliver naltrexone transdermally
• Alendronate (Fosamax®), highly charged, difficult to formulate.
• Raloxifene (Evista®)
• Difficult to solubilize API’s

Find out more about our key areas of application. Go to Research.